Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
ReutersFri, February 27, 2026 at 5:57 PM UTC
0
A screen displays the company logo for Generate:Biomedicines during the company's IPO at the Nasdaq MarketSite in New York City, U.S.,February 27, 2026. REUTERS/Jeenah Moon
Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings.
Advertisement
(Reporting by Pragyan Kalita in Bengaluru; Editing by Sahal Muhammed)
Source: “AOL Money”
